• Explore /
  • Poster
  • / 5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.

5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.

Abstract Poster

Authors

null

Donald B. Fuller

Genesis Healthcare Partners, San Diego, CA

Donald B. Fuller , Brent L. Kane , Clinton A. Medbery , Kelly Underhill , James R. Gray , Anuj Peddada , Ronald C. Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

00643617

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 35)

DOI

10.1200/JCO.2017.35.6_suppl.35

Abstract #

35

Poster Bd #

B22

Abstract Disclosures